AI MARKET SCANNING

EISAI CO LTD

📅 Next Catalyst: Nov 10, 2026 (☀️ Open) 🏛️ TOKYO STOCK EXCHANGE 📁 Healthcare 🏭 Drug Manufacturers – Specialty & Generic
AVG HISTORICAL GAP +0.00%
MAX GAP RECORD -4.45%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $4523.T
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 10, 2026 Earnings Release 2026-11-10 (BEFORE OPEN) 🔮 UPCOMING 🔒
Aug 03, 2026 Earnings Release 2026-08-03 (BEFORE OPEN)
-0.44%
May 15, 2026 Earnings Release 2026-05-15 (AFTER CLOSE)
-4.45%
Feb 09, 2026 Earnings Release 2026-02-09 (BEFORE OPEN)
+2.99%
Nov 05, 2025 Earnings Release 2025-11-05 (BEFORE OPEN)
+0.60%
Aug 05, 2025 Earnings Release 2025-08-05 (AFTER CLOSE)
+2.69%
May 15, 2025 Earnings Release 2025-05-15 (BEFORE OPEN)
-1.83%
Feb 07, 2025 Earnings Release 2025-02-07 (BEFORE OPEN)
-0.76%

VOLATILITY & GAP BIAS

AVG GAP MOVE 1.5%
Bullish Gaps (4)
Bearish Gaps (4)
Neutral / Flat (7)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $4523.T

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-27 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 1266m +3.57%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils;…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗